Date:3/19/2012

clinical studies; diaDexus' high degree of customer concentration, including the downward pressure that its largest customers may be able to exert on its product pricing; diaDexus' relationship with key customers, including GlaxoSmithKline, the licensor of Lp-PLA(2); diaDexus' reliance on a sole source third party manufacturer to manufacture and supply diaDexus' PLAC® ELISA Test; third party payors' acceptance of and reimbursement for the PLAC® Test; diaDexus' ability to develop and commercialize new products and services; various risks associated with the international expansion of diaDexus' business; diaDexus' ability to successfully launch and commercialize the PLAC® Test for Lp-PLA(2) Activity in Europe, and its dependence on its distributors for foreign sales of that test; diaDexus' ability to initiate and continue to manufacture the PLAC® Test for Lp-PLA(2) Activity at its facility in South San Francisco, California; the adequacy of diaDexus' intellectual property rights; diaDexus' ability to satisfy its obligations under its license agreements, to maintain its license rights under those license agreements and to enter into any necessary licenses on acceptable terms; diaDexus' ability to attract, retain and motivate qualified personnel; the effects of U.S. and foreign government regulations and diaDexus' ability to comply with such regulations; diaDexus' limited revenue and cash resources; and diaDexus' significant corporate expenses, including real estate lease liabilities and expenses associated with being a public company. Additional factors that could cause diaDexus' results to differ materially from those described in the forward-looking statements can be found in diaDexus' most recent annual report on Form 10-K and subsequent quarterly reports on Form 10-Q and other reports filed with the Securities and Exchange Commission, and available at the SEC's web site at www.sec.gov. The information set forth
'/>"/>

SOURCE diaDexus, Inc. Copyright©2010 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5 6
Related medicine technology :

1. diaDexus, Inc. Reports 2011 Fourth Quarter and Year-End Financial Results
2. diaDexus, Inc. to Host Webcast March 15, 2012 on 2011 Fourth Quarter and Year-End Financial Results
3. diaDexus, Inc. Reports 38% Year-Over-Year Revenue Growth for 2011 Third Quarter
4. diaDexus, Inc. Reports 2011 First Quarter Financial Results
5. diaDexus, Inc. Reports 2010 Third Quarter Financial Results
6. diaDexus, Inc. Adds Two New Directors; Corporate Overview & 3Q Results Webcast Set for November 16, 2010
7. Elekta Highlights Latest Version of MOSAIQ Oncology Information System at HIMSS12 Meeting
8. Bionovo to Host Conference Call to Discuss 2011 Highlights and Year-End Financial Results
9. UBM Medicas Musculoskeletal Network Highlights Key Orthopedic Findings From AAOS
10. Zacks Voice of the People highlights opportunities with Walgreen, Occidental Petroleum and Brown & Brown
11. Ampio Pharmaceuticals Reports Full-Year 2011 Financial Results and Milestone Highlights for 2011